Fluticasone Furoate

證據等級: L5

預測適應症: 10 個

Fluticasone Furoate: From Allergic Rhinitis/Asthma to Atopic Eczema

One-Sentence Summary

Fluticasone furoate is a potent inhaled/intranasal corticosteroid, most widely known as an ingredient in respiratory combination products (e.g. fluticasone furoate/vilanterol, fluticasone furoate/umeclidinium/vilanterol). The TxGNN model’s top-ranked candidate for this drug is Atopic Eczema, with 11 clinical trials and 2 publications currently retrieved, though none of the trials use fluticasone furoate itself — they involve the related ester fluticasone propionate or comparator drugs.

Quick Overview

Item	Content
Original Indication	Not stated in the Evidence Pack (`original_indications` is empty and no ARTG licence text is available). Fluticasone furoate is generally known as an inhaled/intranasal corticosteroid used for allergic rhinitis and, in combination products, asthma/COPD — this is general pharmacological background, not sourced from the Evidence Pack.
Predicted New Indication	Atopic Eczema
TxGNN Prediction Score	99.98%
Evidence Level	L3
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for fluticasone furoate in this Evidence Pack (flagged as a High-severity data gap). Based on general pharmacological knowledge, fluticasone furoate is a corticosteroid receptor agonist; drugs of this class suppress local inflammation and the Th2 cytokine pathway, which is the standard mechanism underlying corticosteroid treatment of atopic eczema.

The predicted link is therefore mechanistically plausible at the drug-class level — topical/inhaled corticosteroids are already first-line therapy for atopic dermatitis. However, the retrieved evidence is built almost entirely on fluticasone propionate (a different ester of fluticasone) and on tacrolimus comparator trials, not on fluticasone furoate itself. Extrapolating efficacy from the propionate ester to the furoate ester carries real uncertainty, since the two esters differ in potency, receptor affinity and formulation (furoate is typically inhaled/intranasal, propionate has established topical dermatological formulations). No fluticasone-furoate-specific dermatology RCT was identified.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT03594565	Early Phase 1	Completed	13	Case series on topical nasal steroids for skin reactions to continuous glucose monitors in children with type 1 diabetes
NCT00546000	Phase 4	Completed	56	Open-label study of Cutivate (fluticasone propionate) lotion 0.05% and its effect on the HPA axis in paediatric atopic dermatitis
NCT01915914	Phase 4	Completed	107	Intermittent (twice-weekly) fluticasone propionate 0.05% cream plus regular moisturiser to reduce relapse risk in stabilised paediatric atopic dermatitis
NCT00119158	Phase 4	Completed	90	Exploratory vehicle-controlled study combining pimecrolimus (Elidel) and fluticasone (Cutivate) cream in severe atopic dermatitis lesions
NCT00689832	Phase 4	Completed	487	Comparative RCT of tacrolimus 0.03% vs fluticasone 0.005% ointment in children ≥2 years with moderate-severe atopic dermatitis (tacrolimus is the primary intervention)
NCT00690105	Phase 4	Completed	577	Comparative RCT of tacrolimus 0.1% vs fluticasone 0.005% ointment in adults with facial atopic dermatitis (“red face” lesions)
NCT00616538	Phase 4	Completed	121	Pilot RCT comparing EpiCeram barrier-repair device vs mid-strength fluticasone propionate 0.05% in paediatric atopic dermatitis
NCT03742414	Phase 2	Active, not recruiting	398	SEAL study: proactive skin-barrier care (tri-lipid cream plus fluticasone propionate) to prevent progression of infant atopic dermatitis and food allergy
NCT00426283	Phase 2	Completed	42	Swallowed high-dose fluticasone propionate vs placebo in eosinophilic oesophagitis — different route and indication, low relevance
NCT01772056	Phase 3	Terminated	54	RCT of twice-weekly fluticasone propionate 0.05% cream maintenance therapy to reduce relapse in mild-moderate paediatric atopic dermatitis

Note: one additional trial (NCT04706559, oral probiotics in paediatric atopic dermatitis) was excluded from this table as it does not involve fluticasone at all. No ANZCTR-registered trials were identified.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
19571596	2009	Review	Neuroimmunomodulation	Reviews HPA-axis suppression risk associated with intranasal corticosteroids used across allergic rhinitis, asthma and atopic dermatitis
40066386	2025	Case Report	Indian Journal of Otolaryngology and Head and Neck Surgery	Case report on allergen immunotherapy in a patient with autoimmune disease; atopic dermatitis and corticosteroid use are mentioned only as background context

Australia Market Information

Fluticasone furoate has no ARTG entries recorded in this Evidence Pack (total_licenses = 0), and market status is recorded as Not marketed. No product/dosage-form/indication data is therefore available to tabulate.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. This Evidence Pack has no key warnings, contraindications or drug–drug interaction data on file — notably, TGA/TFDA product-label warnings are flagged internally as a Blocking-severity data gap, meaning a formal safety review cannot proceed until this is resolved.

Conclusion and Next Steps

Decision: Hold

Rationale:

The underlying model output for this candidate is “Research Question” at decision stage S1 (evidence level L3) — reflecting that all supporting trials use a different ester (fluticasone propionate) or a different drug (tacrolimus) rather than fluticasone furoate itself, and the two available literature items are indirect (a general HPA-axis review and an unrelated case report).
Fluticasone furoate has no Australian market presence (0 ARTG entries), and mechanism-of-action and PI safety data are both flagged as gaps (one Blocking, one High severity), so no safety assessment can currently be completed.

To proceed, the following is needed:

TGA-approved Product Information (warnings, contraindications, DDI) — currently a Blocking data gap
Confirmed mechanism-of-action data from DrugBank — currently a High-severity data gap
A fluticasone-furoate-specific (not propionate) trial or pharmacokinetic bridging study in atopic dermatitis, to justify cross-ester extrapolation
Confirmed original/registered indication text, since original_indications is currently empty in the source data

Note for reviewers: this Evidence Pack also contains a substantially stronger repurposing signal for fluticasone furoate under obstructive lung disease (rank 9, evidence level L1, decision stage S3, “Proceed with Guardrails” — supported by multiple completed Phase 3 RCTs including IMPACT, FULFIL and SUMMIT for FF/UMEC/VI and FF/VI, which are already marketed combination therapies for COPD). If the goal is to identify the best-supported candidate for this drug rather than the highest raw TxGNN score, a separate report on that indication is recommended.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.